Halozyme Therapeutics Announces Johnson & Johnson Gets FDA Approval For TECVAYLI In Combination With DARZALEX FASPRO To Treat Adults With Relapsed Or Refractory Multiple Myeloma
unknown
📅 Published: 2026-03-06 09:01
📰 Source: Benzinga
📝 Words: 28
📝 Article Content
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI® (teclistamab-cqyv) in combination
📄 Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI® (teclistamab-cqyv) in combination
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-13 18:10:42
Updated At:
2026-03-13 18:10:42
Scraping Job ID:
N/A
Stock Mentions:
AMP - Ameriprise Financial Inc.
Relevance: N/A